Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

<ul><li>US-based drug manufacturer, Gilead earlier announced non-exclusive voluntary licensing agreements with Indian pharmaceutical companies including Cipla, Hetero, Dr. Reddy's Laboratories and others.</li><li>The agreements allow these companies to manufacture remdesivir for distribution in 127 countries.</li><li>Indian pharmaceutical company, Hetero has priced the drug at ₹5,400, whereas Cipla said the drug would be priced below ₹5,000. </li></ul>While the <a href="https://www.businessinsider.in/science/news/the-us-bought-up-90-of-the-worlds-supply-of-remdesivir-for-the-next-3-months-and-patents-mean-many-countries-wont-be-able-to-get-any/articleshow/76729248.cms">Trump administration is hoarding up</a> the stock of antiviral drug remdesivir from US-based Gilead Sciences for the next three months, leaving hardly any stock of the key Covid-19 drug for the rest of the world— but this might not be something that India has to worry about. To expand the supply of remdesivir drug,<a href="https://www.livemint.com/companies/news/zydus-cadila-signs-licensing-pact-with-gilead-for-covid-19-drug-remdesivir-11591975212351.html"> Gilead earlier announced</a> non-exclusive voluntary licensing agreements with Indian pharmaceutical companies. Remdesivir is considered a key drug in the fight against Covid-19 as a randomised clinical trial conducted with the drug on 1,063 patients over 60 centres across US, Europe and Asia <a href="https://www.businessinsider.in/international/news/us-secures-almost-entire-world-stock-of-covid-19-drug-remdesivir-from-gilead-sciences-for-the-next-three-months/articleshow/76730789.cms">demonstrated faster time</a> to clinical recovery in Covid-19 infected patients. The agreements allow these companies to manufacture remdesivir for distribution in 127 countries. <table style="width: 144pt;"> </colgroup></colgroup> <tbody><tr> <td class="xl65" style="height:15.0pt;width:48pt">Companies licensed for remdesivir manufacturing in India</td> <td class="xl65" style="border-left-width: initial; border-left-style: none; width: 48pt;">approval</td> <td class="xl65" style="border-left-width: initial; border-left-style: none; width: 48pt;"> price</td> </tr> <tr> <td class="xl65" style="height: 15pt; border-top-width: initial; border-top-style: none;">Cipla </td> <td class="xl66" style="border-top-width: initial; border-top-style: none; border-left-width: initial; border-left-style: none;">approved</td> <td class="xl65" style="border-top-width: initial; border-top-style: none; border-left-width: initial; border-left-style: none;">₹5,000</td> </tr> <tr> <td class="xl65" style="height: 15pt; border-top-width: initial; border-top-style: none;">Hetero </td> <td class="xl66" style="border-top-width: initial; border-top-style: none; border-left-width: initial; border-left-style: none;">approved </td> <td class="xl65" style="border-top-width: initial; border-top-style: none; border-left-width: initial; border-left-style: none;">₹ 5,400 </td> </tr> <tr> <td class="xl65" style="height: 15pt; border-top-width: initial; border-top-style: none;">Jubilant Lifesciences</td> <td class="xl65" style="border-top-width: initial; border-top-style: none; border-left-width: initial; border-left-style: none;">pending for approval</td> <td class="xl65" style="border-top-width: initial; border-top-style: none; border-left-width: initial; border-left-style: none;">N/A</td> </tr> <tr> <td class="xl65" style="height: 15pt; border-top-width: initial; border-top-style: none;">Dr. Reddy's Laboratories Ltd</td> <td class="xl65" style="border-top-width: initial; border-top-style: none; border-left-width: initial; border-left-style: none;">pending for approval</td> <td class="xl65" style="border-top-width: initial; border-top-style: none; border-left-width: initial; border-left-style: none;">N/A</td> </tr> <tr> <td class="xl65" style="height: 15pt; border-top-width: initial; border-top-style: none;">Zydus Cadila</td> <td class="xl65" style="border-top-width: initial; border-top-style: none; border-left-width: initial; border-left-style: none;">pending for approval</td> <td class="xl65" style="border-top-width: initial; border-top-style: none; border-left-width: initial; border-left-style: none;">N/A</td> </tr> <tr> <td class="xl65" style="height: 15pt; border-top-width: initial; border-top-style: none;">Ferozsons Laboratories</td> <td class="xl65" style="border-top-width: initial; border-top-style: none; border-left-width: initial; border-left-style: none;">pending for approval</td> <td class="xl65" style="border-top-width: initial; border-top-style: none; border-left-width: initial; border-left-style: none;">N/A</td> </tr></tbody></table>Under the <a href="https://www.businessinsider.in/international/news/us-secures-almost-entire-world-stock-of-covid-19-drug-remdesivir-from-gilead-sciences-for-the-next-three-months/articleshow/76730789.cms">licensing agreements,</a> the companies have a right to receive a technology transfer of the Gilead manufacturing process for Remdesivir to enable them to scale up production more quickly. The licensees can also set their own prices for the generic product they produce, while they are still subjected to regulatory approval from authorities. Earlier last week India's top drug regulator had given the nod to Cipla and Hetero for marketing authorisation of antiviral drug Remdesivir only for "restricted emergency use" on COVID-19 patients. Hetero has priced the drug at ₹5,400, whereas Cipla said the drug would be priced below ₹5,000. SEE ALSO: <a href="https://www.businessinsider.in/international/news/us-secures-almost-entire-world-stock-of-covid-19-drug-remdesivir-from-gilead-sciences-for-the-next-three-months/articleshow/76730789.cms" data-type="tilCustomLink">US secures almost entire world stock of Covid-19 drug remdesivir from Gilead Sciences for the next three months</a> <a href="https://www.businessinsider.in/science/news/the-us-bought-up-90-of-the-worlds-supply-of-remdesivir-for-the-next-3-months-and-patents-mean-many-countries-wont-be-able-to-get-any/articleshow/76729248.cms" data-type="tilCustomLink">The US bought up 90% of the world's supply of remdesivir for the next 3 months, and patents mean many countries won't be able to get any</a>

These are the companies manufacturing COVID-19 drug Remdesivir in India

Bogged by the Covid-19 second wave, <keyword id="13126" type="COMPANY" weightage="20" keywordseo="Maharashtra">Maharashtra</keyword> is now left with only three days of <keyword id="3772566" type="PERSON" weightage="20" keywordseo="vaccine-stocks">vaccine stocks</keyword>. The state is also plagued by shortages of oxygen and Ramdesivir medicines to combat the growing scourge, now soaring above half-lakh new infections daily, a top official said here on Wednesday. "We have around 14 lakh doses left available That's the stock sufficient for only three days. Our weekly requirement is around 40 lakh doses to enable us to vaccinate up to 500,000 people. In the current surge, the vaccine is the only 'Ram-baan' available," <keyword id="6354750" type="COMPANY" weightage="20" keywordseo="health">Health</keyword> Minister <keyword id="211932" type="PERSON" weightage="20" keywordseo="Rajesh-Tope">Rajesh Tope</keyword> told mediapersons here this afternoon. Sounding grim, Tope said that he has already informed the situation to <keyword id="700200" type="COMPANY" weightage="20" keywordseo="Union-Health">Union Health</keyword> Minister <keyword id="196226" type="PERSON" weightage="20" keywordseo="Harsh-Vardhan">Harsh Vardhan</keyword> on the prevailing scenario at a video-conference of the health ministers of nine worst-hit states. Owing to the shortage of vaccines at various vaccination centres, the people are being sent back and the state has demanded that people in the vulnerable 20-45 age groups should be given the life-saver jab on priority, he said. Close on the heels of Tope's announcement, the <keyword id="53938" type="COMPANY" weightage="20" keywordseo="Brihanmumbai-Municipal-Corporation">BrihanMumbai Municipal Corporation</keyword> (<keyword id="48434" type="COMPANY" weightage="20" keywordseo="BMC">BMC</keyword>) Mayor Kishori Pednekar also said that vaccine stocks in Mumbai are on the verge of getting over. "We have barely 100,000 doses left now. Most of our vaccines are being supplied to the government hospitals. If we don't get fresh stocks soon, we may not be able to administer the second dose to the people," a worried Pednekar told mediapersons. Health Secretary Pradeep Vyas has cautioned that most districts will run out of vaccine stocks in a couple of days or so, and it would be impossible to vaccinate an estimated 500,000 people daily. SEE ALSO: <a href="https://www.businessinsider.in/business/startups/news/for-the-third-consecutive-day-a-new-unicorn-is-born-from-india-as-pharmeasy-joins-the-billion-dollar-club/articleshow/81943929.cms">For the third consecutive day, a new unicorn is born from India as PharmEasy joins the billion dollar club</a> <a href="https://www.businessinsider.in/stock-market/news/barbeque-nation-ipo-shares-list-at-2-discount/articleshow/81944700.cms">Barbeque Nation bears the brunt of an uncertain future – shares list at 2% discount</a> <a href="https://www.businessinsider.in/policy/news/rbi-has-increased-mobile-wallets-limit-with-2-lakh-and-need-full-kyc-also-for-mobile-wallets/articleshow/81946037.cms">You need to do full KYC for mobile wallets too – but you can store twice the amount of money</a>

Maharashtra left with only three days COVID-19 vaccine stocks,  says Health Minister Rajesh Tope

Ahmemdabad, Aug 17 () Surat is better positioned now to defeat the coronavirus pandemic than last month as reflected in encouraging signs like drop in growth rate of new cases, doubling rate and deaths besides more testing, the state government told the Gujarat High Court on Monday. While hearing aPIL on issues related to COVID-19 and lockdown, a division bench of Chief Justice Vikram Nath and Justice J B Pardiwalahad earlier asked the government to file a reply on its preparedness to tackle the pandemic in the south Gujarat district. The bench had earlier observed that "delayed response" from the government and local administration has caused the pandemic situation to go "from bad to worse. Surat has been reporting the highest number of COVID- 19 cases in the last few weeks, overtaking Ahmemdabad which was earlier the worst-hit district in Gujarat. "In every domain, right from testing per million per day, recovery rate, growth rate of new cases, doubling rate, death rate, operational Dhanvantri raths, 104 calls attended, total beds availability, the (Surat) district today is far better positioned to defeat the pandemic. "And the said fact is reflected from the trends right from July 4 to August 10," the government told the HC. To illustrate the point, the government furnished figures, as per which the COVID-19 recovery rate of Surat city improved to 77.3 per cent on August 13 from 64 per cent on July 10, while testing per million rose to 1,288.6 compared to 130 on July 4. Also, growth rate of new coronavirus cases fell to 1.82 per cent on August 13 compared to 4.13 per cent on July 4. Daily positive case was 181 on August 13 compared to 205 on July 4, peaking at 217 on July 15 and July 30, the government told the bench. Fatalities dropped to four a day after rising to 14 a day on July 21, it said. Informing the court about initiatives taken to control the pandemic, the government said 17 COVID-19 isolation centres were made operational, a "first-of-its-kind" measure in the country. As many as 110 'Dhanvantari' raths are being operated daily attending an average 275 individuals. Also, 297 convalescent plasmas were collected to treat over 260 patients, of which 60 per cent have shown positive response, the government said. 'Dhanvantari' raths (vehicles) function as mobile OPDs. The Surat civic body has also adopted the strategy of rapid response to '104' helpline to identify patients early and set up Suraksha Kavach Committees to ensure strict enforcement of COVID-19 norms in containment zones, it said. The Surat Municipal Corporation (SMC) is making extensive use of pulse oximeter, has set up zone-wise 'war rooms', started training for diamond, textile industry workers, migrant labourers besides pushing for plasma therapy treatment, among other steps, it said. In terms of infrastructure, beds have been made available in two government hospitals and 44 private hospitals to treat COVID-19 patients, the government said. Around 900 patients have been administered Tocilizumab injections so far, and more than 2,200 patients given Ramdesivir medicine, both free of cost, it told the court. Additional 400 ventilators have been provided to hospitals, including private ones, in Surat, the government said. KA PD RSY RSY

You Searched For "ramdesivir medicine" and got 3 results

These are the companies manufacturing COVID-19 drug Remdesivir in India

Navdeep Yadav

Maharashtra left with only three days COVID-19 vaccine stocks, says Health Minister Rajesh Tope

IANS

Surat now better placed to defeat COVID-19: Govt tells HC

PTI

Popular Keywords

Buying Guides